On Jun 29, 2018 “Outperform” Rating Received InflaRx (IFRX) at Raymond James with $44 Target.

June 29, 2018 - By Nicole Mills

What Price Target Has Raymond James Given InflaRx (IFRX)

Coverage of InflaRx (IFRX)‘s stock began on 28 June. Raymond James has $44 target and issued “Outperform” rating which gives 43.51 % upside potential on IFRX stock.

InflaRx N.V. (NASDAQ:IFRX) Ratings Coverage

In total 5 analysts cover InflaRx (IFRX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 9 are the (IFRX)’s analyst reports since February 8, 2018 according to StockzIntelligence Inc. On Wednesday, February 7 the company was initiated by FBR Capital. On Thursday, May 17 the firm has “Buy” rating by FBR Capital given. In Monday, April 2 report Leerink Swann maintained it with “Buy” rating and $3600 target. On Thursday, March 8 FBR Capital maintained the shares of IFRX in report with “Buy” rating. On Friday, May 18 the firm earned “Buy” rating by Leerink Swann. On Thursday, March 29 the rating was maintained by FBR Capital with “Buy”.

The stock increased 2.85% or $0.85 during the last trading session, touching $30.66.InflaRx N.V. has volume of 27,210 shares. Since June 29, 2017 IFRX has 0.00% and is . IFRX underperformed the S&P500 by 12.57%.

InflaRx N.V. (NASDAQ:IFRX) is anticipated to publish earnings on August, 16., according to RTT. Last quarter $-0.49 earnings per share was reported. Analysts forecasts -18.37 % EPS growth this quarter.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe.The firm is valued at $786.80 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Last it reported negative earnings. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Another two news for InflaRx N.V. (NASDAQ:IFRX) were recently posted by: Globenewswire.com on June 05, 2018 with title “InflaRx Opens New Research Facility in Ann Arbor”. The other Nasdaq.com‘s article was titled “InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis” and posted on June 28, 2018.

InflaRx N.V. (NASDAQ:IFRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: